This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Expression of Longevity Genes in Response to Extended Fasting (FEELGOOD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier:
NCT01059760
First received: January 28, 2010
Last updated: April 18, 2017
Last verified: March 2011
January 28, 2010
April 18, 2017
January 2010
August 2010   (Final data collection date for primary outcome measure)
  • Change From Baseline in Participant Glucose When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Human Growth Hormone (HGH) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Insulin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
    HOMA-IR is used to measure the severity of insulin resistance. Healthy Range: 1.0 (0.5-1.4) Less than 1.0 is optimal Above 1.9 indicates early insulin resistance Above 2.9 indicates significant insulin resistance
  • Change From Baseline in Participant Glycogen-Like Protein-1 (GLP-1) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Adiponectin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Fibroblast Growth Factor-21 (FGF-21) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant White Blood Cell Count (WBC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Hemoglobin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Red Blood Cell Count (RBC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Hematocrit When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Platelet Count When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Mean Corpuscular Volume (MCV) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Mean Corpuscular Hemoglobin (MCH) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Mean Corpuscular Hemoglobin Concentration (MCHC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Red Cell Distribution Width (RDW) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Mean Platelet Volume (MPV) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Bicarbonate When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Sodium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Chloride When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Blood Urea Nitrogen (BUN) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Calcium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Potassium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Creatinine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Total Cholesterol (TC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Low-Density Lipoprotein Cholesterol (LDL-C) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant High-Density Lipoprotein Cholesterol (HDL-C) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Triglycerides When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant TC/HDL Ratio When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Weight When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Waist Circumference When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Systolic Blood Pressure (SBP), Supine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant Diastolic Blood Pressure (DBP), Supine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  • Change From Baseline in Participant High Sensitivity C-Reactive Protein (hsCRP) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
Outcome measures will include the primary endpoint of gene expression (mRNA) [ Time Frame: 3 days ]
Complete list of historical versions of study NCT01059760 on ClinicalTrials.gov Archive Site
Not Provided
Secondary outcome measures will include cardiovascular risk factors such as glucose level, weight, and high sensitivity C-reactive protein as well as other indicators of inflammation and metabolic health. [ Time Frame: 3 days ]
Not Provided
Not Provided
 
Expression of Longevity Genes in Response to Extended Fasting
Expression of Longevity Genes in Response to Extended Fasting
The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.
Coronary heart disease (CHD) is the largest contributor to morbidity and mortality in the Western world and is associated with high-calorie diet, high body mass, and a variety of other factors. CHD can lead to myocardial infarction (MI) and other embolic events. A growing body of evidence suggests that relatively low caloric intake in the diets of a variety of animals increases longevity and preliminary evidence among humans indicates that such caloric restriction reduces risk factors for CHD, including cholesterol levels, blood pressure, glucose, and obesity. Caloric restriction has also been shown to alter the expression of certain genes, especially the forkhead box (FOX) O and sirtuin (SIRT) genes whose over-expression has been shown to increase longevity in animal models. Extended avoidance of caloric intake, also called fasting or short-term starvation, has been shown to increase expression of the FOXA genes that have similar sequence and function as the FOXO genes and that have been shown to increase longevity among animals regardless of FOXO function. We recently demonstrated that the risk of CHD was significantly lower among patients who reported a history of routine periodic extended fasting. The two primary hypotheses for this observation are that fasting may improve individual ability to control dietary intake or that fasting may initiate a cascade of protective mechanisms that preserve cellular and metabolic health.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cardiovascular Disease
  • Behavioral: Fasting First
    28±4 hours of water-only fasting followed by 28±4 hours fed
  • Behavioral: Fed First
    28± 4 hours fed followed by 28± 4 hours of fasting
  • Fasting Day First
    28±4 hours of water-only fasting followed by 28±4 hours fed
    Intervention: Behavioral: Fasting First
  • Fed Day First
    28± 4 hours fed followed by 28± 4 hours of fasting
    Intervention: Behavioral: Fed First

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
October 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The volunteer (male or non-pregnant female, any ethnicity) must be >18 years of age.
  2. The volunteer must either have a body mass index of 25.0-35.0 kg/m2 or the combination of a body mass index of 18.5-24.9 kg/m2 and two or more previously or currently measured symptoms of the metabolic syndrome (fasting glucose≥110 mg/dL, triglycerides≥150 mg/dL, high-density lipoprotein cholesterol<40 mg/dL in males or <50 mg/dL in females, systolic blood pressure≥130 mmHg or diastolic blood pressure≥85 mmHg, or waist circumference≥40 inches in males or ≥36 inches in females [glucose and cholesterol levels may be self-reported]).
  3. The volunteer has not routinely participated in caloric restriction (deliberate limitation of caloric intake of <80% than the FDA-recommended daily caloric intake) within the last 2 years, has not participated in extended fasting (>12 hours at a time) for at least a year, and does not deliberately skip meals as a routine dietary practice.

Exclusion Criteria:

  1. Body mass index <18.5 or >35 kg/m2.
  2. Current active cancer treatment, treatment with immunosuppressive medications, or solid organ transplantation within 1 year.
  3. Presence of immunosuppressive disease, myocardial infarction, peripheral vascular disease, or stroke within the past year.
  4. Use of insulin.
  5. Although it is unlikely fasting will harm the pregnant or lactating woman, the dietary restrictions placed on the participant for the duration of the study may conflict with dietary recommendations for pregnant or lactating women. Women of child bearing potential, therefore, will meet an exclusion if they become pregnant.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01059760
154-002
No
Not Provided
Not Provided
Intermountain Health Care, Inc.
Intermountain Health Care, Inc.
Not Provided
Principal Investigator: Benjamin D Horne, PhD Intermountain Medical Center
Intermountain Health Care, Inc.
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP